How should a dormant (asymptomatic) herpes simplex infection be treated?

Treatment of Dormant (Asymptomatic) Herpes Infection

For truly asymptomatic HSV-2 infection (no recognized symptoms), daily suppressive antiviral therapy should be offered if the patient wishes to reduce transmission risk to sexual partners, with acyclovir 400 mg twice daily, valacyclovir 500 mg once daily, or famciclovir 250 mg twice daily as first-line options. 1

Understanding "Dormant" Herpes

The term "dormant" requires clarification, as approximately 20% of HSV-2 seropositive persons report no genital symptoms, yet asymptomatic viral shedding occurs on about 3% of days even without recognized outbreaks 2, 3. Most horizontal and vertical HSV transmission occurs during these unrecognized shedding episodes 3. Many patients labeled as "asymptomatic" can learn to recognize subtle genital signs as HSV recurrences after education 3.

Treatment Approach Based on Clinical Scenario

For Patients with No Recognized Symptoms (True Asymptomatic Infection)

Suppressive therapy is optional but recommended if:

• The patient has a sexual partner who is HSV-2 seronegative
• The patient wishes to reduce transmission risk
• The patient is concerned about unrecognized shedding

Recommended suppressive regimens 1:

• Acyclovir 400 mg orally twice daily (most established safety data, documented efficacy up to 6 years)
• Valacyclovir 500 mg orally once daily (convenient dosing, though less effective if patient later develops ≥10 recurrences/year)
• Valacyclovir 1000 mg orally once daily (alternative dosing)
• Famciclovir 250 mg orally twice daily

Critical caveat: Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 1. Condom use should still be encouraged during all sexual exposures 1, 4.

For Patients with Infrequent or Unrecognized Recurrences

If the patient has HSV-2 but doesn't recognize symptoms, patient education is the first priority 4. Many will identify previously unrecognized mild symptoms once educated about atypical presentations.

After education, offer two management strategies:

1. Episodic therapy (for patients who learn to recognize prodrome or early lesions) 1:

   • Provide prescription in advance to initiate at first sign of symptoms
   • Treatment must start during prodrome or within 1 day of lesion onset for benefit
   • Acyclovir 800 mg twice daily for 5 days, OR
   • Acyclovir 400 mg three times daily for 5 days, OR
   • Famciclovir 125 mg twice daily for 5 days, OR
   • Valacyclovir 500 mg twice daily for 5 days

2. Daily suppressive therapy (preferred if ≥6 recurrences per year once recognized) 1:

   • Reduces recurrence frequency by ≥75%
   • Same regimens as listed above for asymptomatic patients
   • Reassess after 1 year to determine if continued therapy needed, as recurrence frequency naturally decreases over time 1

Special Populations

HIV-Infected Patients

• Require higher doses: acyclovir 400 mg orally 3-5 times daily 1
• Suppressive therapy does not reduce HSV-2 transmission risk in HIV/HSV-2 coinfected persons 2
• Famciclovir 500 mg twice daily effective for reducing recurrences and subclinical shedding 1

Pregnant Women

• All childbearing-aged women with genital herpes should inform obstetric providers about HSV infection 1, 4
• Management during pregnancy requires specialized protocols (see pregnancy-specific guidelines 5)

Important Counseling Points

All patients with HSV-2 (symptomatic or asymptomatic) should be counseled about 1:

• Natural history emphasizing potential for recurrent episodes and asymptomatic shedding
• Sexual transmission can occur during asymptomatic periods
• Condom use during all sexual exposures with new or uninfected partners
• Abstinence when lesions or prodromal symptoms present
• Neonatal transmission risk (for all patients, including men)

Monitoring and Follow-up

• After 1 year of continuous suppressive therapy, discontinue to reassess recurrence rate and patient's psychological adjustment 1
• Acyclovir resistance has not been clinically significant in immunocompetent patients on long-term suppression 1
• Safety documented for acyclovir up to 6 years; valacyclovir and famciclovir data limited to 1 year as of 1998 guidelines 1

What NOT to Do

• Do not treat truly asymptomatic patients with episodic therapy - there are no symptoms to treat
• Do not use topical acyclovir - substantially less effective than oral therapy 4
• Do not assume suppressive therapy eliminates transmission risk - it reduces but does not eliminate viral shedding 1
• Do not screen asymptomatic low-risk populations - USPSTF recommends against routine HSV-2 screening 2

The evidence consistently supports that while antiviral therapy provides partial control of symptoms and reduces transmission risk, it neither eradicates latent virus nor affects long-term recurrence patterns after discontinuation 4, 6.